Coloplast (COLO) AGM 2024 summary

Opening remarks and agenda

• AGM confirmed as lawfully convened, with 87.79% of votes represented; agenda covered the annual report, profit distribution, remuneration, and board and auditor elections.

Financial performance review

• FY 2023/24 net revenue rose 10% to DKK 27,030m, with 8% organic growth; EBIT margin was 27% before special items, down from 28% the prior year.

• Net profit was DKK 5,052m and free cash flow DKK 1,430m; net interest-bearing debt was DKK 21.8bn.

• Total FY dividend of DKK 22.00 per share, including the DKK 5.00 interim dividend and DKK 17.00 year-end dividend, was approved; payout ratio was 98%.

• FY 2024/25 outlook: 8–9% organic growth, 28% EBIT margin before special items, DKK 1.4bn CapEx, and a 22% tax rate.

Board and executive committee updates

• Lars Søren Rasmussen, Niels Peter Louis-Hansen, Annette Brüls, Carsten Hellmann, Jette Nygaard-Andersen, and Marianne Wiinholt were re-elected; Rasmussen was elected Chairman and Louis-Hansen Deputy Chairman.

• Employee-elected directors were Thomas Barfod, Nikolaj Kyhe Gundersen, and Roland Vendelbo Pedersen.

• Two women joined the executive leadership team, bringing senior-level gender diversity to 28%.

• Board evaluation found strong collaboration and high satisfaction with board competencies.